The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases

Current Diabetes Reports

Volumn 16, Issue 6, 2016, Pages

  Sethupathy, Praveen ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anti sense oligonucleotide; Aptamer; Diabetes; Metabolic disease; MicroRNA; Therapeutics

Indexed keywords

MICRORNA;

CANCER PROGNOSIS; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; REVIEW; ANIMAL; COMPLICATION; DIABETIC COMPLICATION; GENETICS; METABOLIC SYNDROME X;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICRORNAS; OBESITY;

EID: 84964523640     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-016-0745-3     Document Type: Review

References (54)

1. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. 2013;9:513–21. doi:10.1038/nrendo.2013.86.
2. Ivey KN, Srivastava D. MicroRNAs as regulators of differentiation and cell fate decisions. Cell Stem Cell. 2010;7:36–41. doi:10.1016/j.stem.2010.06.012.
3. Dumortier O, Hinault C, Van Obberghen E. MicroRNAs and metabolism crosstalk in energy homeostasis. Cell Metab. 2013;18:312–24. doi:10.1016/j.cmet.2013.06.004.
4. Ross SA, Davis CD. The emerging role of microRNAs and nutrition in modulating health and disease. Annu Rev Nutr. 2014;34:305–36. doi:10.1146/annurev-nutr-071813-105729.
5. Archambaud C et al. The intestinal microbiota interferes with the microRNA response upon oral Listeria infection. mBio. 2013;4:e00707–00713. doi:10.1128/mBio.00707-13.
6. Vrijens K, Bollati V, Nawrot TS. MicroRNAs as potential signatures of environmental exposure or effect: a systematic review. Environ Health Perspect. 2015;123:399–411. doi:10.1289/ehp.1408459.
7. Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol. 2013;33:186–92. doi:10.1161/ATVBAHA.112.300139. This review provides a description of how circulating miRNAs may serve as intercellular messengers mediating organ-to-organ communication in health and disease.
8. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6:851–64. doi:10.15252/emmm.201100899.
9. Fernandez-Valverde SL, Taft RJ, Mattick JS. MicroRNAs in beta-cell biology, insulin resistance, diabetes and its complications. Diabetes. 2011;60:1825–31. doi:10.2337/db11-0171.
10. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence. 2012;3:1. doi:10.1186/1758-907X-3-1.
11. van Rooij E. The art of microRNA research. Circ Res. 2011;108:219–34. doi:10.1161/CIRCRESAHA.110.227496.
12. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res. 2012;110:496–507. doi:10.1161/CIRCRESAHA.111.247916.
13. Lanford RE et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198–201. doi:10.1126/science.1178178.
14. Janssen HL et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685–94. doi:10.1056/NEJMoa1209026.
15. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci U S A. 2011;108:21075–80. doi:10.1073/pnas.1118922109.
16. Fu T et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc Natl Acad Sci U S A. 2012;109:16137–42. doi:10.1073/pnas.1205951109.
17. Choi SE et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell. 2013;12:1062–72. doi:10.1111/acel.12135.
18. Trajkovski M et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–53. doi:10.1038/nature10112. This is a seminal study on the role of miR-103/107 in regulating insulin sensitivity in the liver and adipose in murine models of diabetes. These findings have led to the selection of miR-103/107 as a candidate for clinical trials (http://ir.regulusrx.com/releasedetail.cfm?ReleaseID=905305).
19. Kornfeld JW et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature. 2013;494:111–5. doi:10.1038/nature11793.
20. Grueter CE et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012;149:671–83. doi:10.1016/j.cell.2012.03.029.
21. Zhou B et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia. 2012;55:2032–43. doi:10.1007/s00125-012-2539-8.
22. de Guia RM et al. MicroRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis. EMBO J. 2015;34:344–60. doi:10.15252/embj.201490464.
23. Ahn J, Lee H, Jung CH, Jeon TI, Ha TY. MicroRNA-146b promotes adipogenesis by suppressing the SIRT1-FOXO1 cascade. EMBO Mol Med. 2013;5:1602–12. doi:10.1002/emmm.201302647.
24. Ng R et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 2014;60:554–64. doi:10.1002/hep.27153.
25. Kurtz CL et al. Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep. 2015;5:12911. doi:10.1038/srep12911.
26. Foley NH, O’Neill LA. miR-107: a toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. J Leukoc Biol. 2012;92:521–7. doi:10.1189/jlb.0312160.
27. Daimiel-Ruiz L et al. Dietary lipids modulate the expression of miR-107, a miRNA that regulates the circadian system. Mol Nutr Food Res. 2015;59:1865–78. doi:10.1002/mnfr.201570094.
28. Fu T et al. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function. Mol Cell Biol. 2014;34:4130–42. doi:10.1128/MCB.00596-14.
29. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393–403. doi:10.3949/ccjm.78a.10073.
30. Gaudet D et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373:438–47. doi:10.1056/NEJMoa1400283.
31. Dooley J et al. The microRNA-29 family dictates the balance between homeostatic and pathological glucose handling in diabetes and obesity. Diabetes. 2016;65:53–61. doi:10.2337/db15-0770.
32. Kurtz CL et al. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes. 2014;63:3141–8. doi:10.2337/db13-1015.
33. Roderburg C et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53:209–18. doi:10.1002/hep.23922.
34. He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie. 2013;95:1355–9. doi:10.1016/j.biochi.2013.03.010.
35. Ma F et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol. 2011;12:861–9. doi:10.1038/ni.2073.
36. Jiang H, Zhang G, Wu JH, Jiang CP. Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014;31:1509–16. doi:10.3892/or.2014.3036.
37. Ye J, DeBose-Boyd RA. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol. 2011;3. doi:10.1101/cshperspect.a004754.
38. Zhu Y et al. MicroRNA-24/MODY gene regulatory pathway mediates pancreatic beta-cell dysfunction. Diabetes. 2013;62:3194–206. doi:10.2337/db13-0151.
39. Najafi-Shoushtari SH et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328:1566–9. doi:10.1126/science.1189123.
40. Rayner KJ et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570–3. doi:10.1126/science.1189862.
41. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A. 2010;107:12228–32. doi:10.1073/pnas.1005191107.
42. Goedeke L et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med. 2014;6:1133–41. doi:10.15252/emmm.201404046.
43. Marquart TJ, Wu J, Lusis AJ, Baldan A. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2013;33:455–8. doi:10.1161/ATVBAHA.112.300639.
44. Rayner KJ et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404–7. doi:10.1038/nature10486.
45. Rottiers V et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med. 2013;5:212ra162. doi:10.1126/scitranslmed.3006840.
46. Belgardt BF, et al. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med. 2015;21: 619–27. doi:10.1038/nm.3862. This study describes the importance of a specific miRNA family in pancreatic beta cell survival and in the pathophysiology of diabetes. Options for therapeutic silencing of miRNAs in beta cellsin vivoremain limited, and represent an important next frontier in research.
47. Poy MN et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–30. doi:10.1038/nature03076.
48. Poy MN et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A. 2009;106:5813–8. doi:10.1073/pnas.0810550106.
49. Latreille M et al. MicroRNA-7a regulates pancreatic beta cell function. J Clin Invest. 2014;124:2722–35. doi:10.1172/JCI73066.
50. Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16:543–52. doi:10.1038/nrg3978.
51. Lieberman J, Sharp PA. Harnessing RNA interference for therapy: the silent treatment. JAMA. 2015;313:1207–8. doi:10.1001/jama.2015.1241. This review highlights the state-of-the-art in anti-sense oligonucleotide (ASO) technology for therapeutics. It includes a discussion of the RNA aptamer based strategy for targeted delivery of ASOs to specific tissues.
52. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505–10.
53. Gilboa-Geffen A et al. Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. Mol Cancer Ther. 2015;14:2279–91. doi:10.1158/1535-7163.MCT-15-0201-T.
54. Wheeler LA et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther. 2013;21:1378–89. doi:10.1038/mt.2013.77.